Carboxy-terminal sequence variation of LMP1 gene in Epstein-Barr-virus-associated mononucleosis and tumors from Serbian patients

Journal of Medical Virology

Volumn 84, Issue 4, 2012, Pages 632-642

  Banko, Ana ^a   Lazarevic, Ivana ^a   Cupic, Maja ^a   Stevanovic, Goran ^a   Boricic, Ivan ^a   Jovanovic, Tanja ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

EBV genotype; Epstein Barr virus (EBV); Latent membrane protein 1 (LMP1); LMP1 strain

Indexed keywords

LATENT MEMBRANE PROTEIN 1;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENETIC VARIABILITY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MONONUCLEOSIS; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; SERBIA; TUMOR BIOPSY; VIRUS ISOLATION;

CLUSTER ANALYSIS; DNA, VIRAL; GENOTYPE; HERPESVIRUS 4, HUMAN; HUMANS; INFECTIOUS MONONUCLEOSIS; MOLECULAR SEQUENCE DATA; NASOPHARYNGEAL NEOPLASMS; PHYLOGENY; REPETITIVE SEQUENCES, NUCLEIC ACID; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; SERBIA; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 84856816773     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23217     Document Type: Article

References (56)

1. Anwar N, Kingma DW, Bloch AR, Mourad M, Raffeld M, Franklin J, Magrath I, el Bolkainy N, Jaffe ES. 1995. The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: Epidemiologic correlations. Cancer 76: 1245- 1252.
2. Ayadi W, Feki L, Khabir A, Boudawara T, Ghorbel A, Charfeddine I, Daoud J, Frikha M, Hammami A, Karray-Hakim H. 2007. Polymorphism analysis of Epstein-Barr virus isolates of nasopharyngeal carcinoma biopsies from Tunisian patients. Virus Genes 34: 137- 145.
3. Barozzi P, Luppi M, Cagossi K, Maiorana A, Marasca R, Artusi T, Poggi S, Pileri SA, Torelli G. 1999. The oncogenic 30 and 69bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. Ann Oncol 10: 467- 469.
4. Berger C, McQuain C, Sullivan JL, Nadal D, Quesenberry PJ, Knecht H. 1997. The 30-bp deletion variant of Epstein-Barr virus-encoded latent membrane protein-1 prevails in acute infectious mononucleosis. J Infect Dis 176: 1370- 1373.
5. Borisch B, Finke J, Hennig I, Delacretaz F, Schneider J, Heitz PU, Laissue JA. 1992. Distribution and localization of Epstein-Barr virus subtypes A and B in AIDS-related lymphomas and lymphatic tissue of HIV-positive patients. J Pathol 168: 229- 236.
6. Chang CM, Yu KJ, Mbulaiteye SM, Hildesheim A, Bhatia K. 2009. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal. Virus Res 143: 209- 221.
7. Chen CL, Wen WN, Chen JY, Hsu MM, Hsu HC. 1993. Detection of Epstein-Barr virus genome in nasopharyngeal carcinoma by in situ DNA hybridization. Intervirology 36: 91- 98.
8. D'Addario M, Chauvin P. 2000. Ethnic differences in the expression of Epstein-Barr virus latent Membrane protein-1 mutations in nasopharyngeal carcinoma. Mutat Res 457: 69- 78.
9. Dolcetti R, Zancai P, De Re V, Gloghini A, Bigoni B, Pivetta B, De Vita S, Carbone A, Boiocchi M. 1997. Epstein-Barr virus strains with latent membrane protein-1 deletions: Prevalence in the italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood 89: 1723- 1731.
10. Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. 1999. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 261: 79- 95.
11. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M, Busson P. 1988. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 42: 329- 338.
12. Gratama JW, Zutter MM, Minarovits J, Oosterveer MA, Thomas ED, Klein G, Ernberg I. 1991. Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int J Cancer 47: 188- 192.
13. Grunewald V, Bonnet M, Boutin S, Yip T, Louzir H, Levrero M, Seigneurin JM, Raphael M, Touitou R, Martel-Renoir D, Cochet C, Durandy A, Andre P, Lau W, Zeng Y, Joab I. 1998. Amino-acid change in the Epstein-Barr-virus ZEBRA protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa. Int J Cancer 75: 497- 503.
14. Guiretti DM, Chabay PA, Valva P, Stefanoff CG, Barros MH, De Matteo E, Renault IZ, Preciado MV, Hassan R. 2007. Structural variability of the carboxy-terminus of Epstein-Barr virus encoded latent membrane protein 1 gene in Hodgkin's lymphomas. J Med Virol 79: 1722- 1730.
15. Hadhri-Guiga B, Khabir AM, Mokdad-Gargouri R, Ghorbel AM, Drira M, Daoud J, Frikha M, Jlidi R, Gargouri A. 2006. Various 30 and 69bp deletion variants of the Epstein-Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Virus Res 115: 24- 30.
16. Hahn P, Novikova E, Scherback L, Janik C, Pavlish O, Arkhipov V, Nicholls J, Müller-Lantzsch N, Gurtsevitch V, Grässer FA. 2001. The LMP1 gene isolated from Russian nasopharyngeal carcinoma has no 30-bp deletion. Int J Cancer 91: 815- 821.
17. Hall TA. 1999. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95, 98, NT, 2000, XP. Nucl Acids Symp 41: 95- 98.
18. Hannigan A, Wilson JB. 2010. Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Mol Cancer 9: 184- 193.
19. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, Osato T. 1990. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335: 128- 130.
20. Hatzivassiliou E, Mosialos G. 2002. Cellular signaling pathways engaged by the Epstein-Barr virus transforming protein LMP1. Front Biosci 7: d319- d329.
21. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G. 1991. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 72: 2399- 2409.
22. Ikegaya H, Motani H, Sakurada K, Sato K, Akutsu T, Yoshino M. 2008. Forensic application of Epstein-Barr virus genotype: Correlation between viral genotype and geographical area. J Virol Methods 147: 78- 85.
23. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N, Tanaka S, Sato E, Osato T. 1994. Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 91: 9131- 9135.
24. Izumi KM, Kieff ED. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 94: 12592- 12597.
25. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M. 1996. Epstein-Barr virus latent membrane protein-1 oncogene deletions: Correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 88: 242- 251.
26. Klein C, Rothenberger S, Niemeyer C, Bachmann E, Odermatt B, Böhm N, Brandis M, Knecht H. 1995. EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Br J Haematol 91: 938- 940.
27. Klemenc P, Marin J, Soba E, Gale N, Koren S, Strojan P. 2006. Distribution of Epstein-Barr virus genotypes in throat washings, sera, peripheral blood lymphocytes and in EBV positive tumor biopsies from Slovenian patients with nasopharyngeal carcinoma. J Med Virol 78: 1083- 1090.
28. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, Pallesen G. 1993. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82: 2937- 2942.
29. Knecht H, Raphaël M, McQuain C, Rothenberger S, Pihan G, Camilleri-Broët S, Bachmann E, Kershaw GR, Ryan S, Kittler EL, Quesenberry PJ, Schlaifer D, Woda BA, Brousset P. 1996. Deletion variants within the NF-kappa B activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations. Blood 87: 876- 881.
30. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N. 1998. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 95: 11963- 11968.
31. Kumar S, Tamura K, Nei M. 2004. MEGA3: Integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief Bioinform 5: 150- 163.
32. Larcher C, McQuain C, Berger C, Mitterer M, Quesenberry PJ, Huemer HP, Knecht H. 1997. Epstein-Barr virus-associated persistent polyclonal B-cell lymphocytosis with a distinct 69-base pair deletion in the LMP1 oncogene. Ann Hematol 74: 23- 28.
33. Larcher C, Bernhard D, Schaadt E, Adler B, Ausserlechner MJ, Mitterer M, Huemer HP. 2003. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): Implications for a new role of naturally occurring LMP1 variants. Haematologica 88: 1324- 1335.
34. Li SN, Chang YS, Liu ST. 1996. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus. Oncogene 12: 2129- 2135.
35. Li DJ, Bei JX, Mai SJ, Xu JF, Chen LZ, Zhang RH, Yu XJ, Hong MH, Zeng YX, Kang T. 2009. The dominance of China 1 in the spectrum of Epstein-Barr virus strains from Cantonese patients with nasopharyngeal carcinoma. J Med Virol 81: 1253- 1260.
36. Lyons SF, Liebowitz DN. 1998. The roles of human viruses in the pathogenesis of lymphoma. Semin Oncol 25: 461- 475.
37. Mendes TM, Oliveira LC, Yamamoto L, Del Negro GM, Okay TS. 2008. Epstein-Barr virus nuclear antigen-2 detection and typing in immunocompromised children correlated with lymphoproliferative disorder biopsy findings. Braz J Infect Dis 12: 186- 191.
38. Miller WE, Edwards RH, Walling DM, Raab-Traub N. 1994. Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 75: 2729- 2740.
39. Moorthy RK, Thorley-Lawson DA. 1993a. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 67: 1638- 1646.
40. Moorthy RK, Thorley-Lawson DA. 1993b. Biochemical, genetic, and functional analyses of the phosphorylation sites on the Epstein-Barr virus-encoded oncogenic latent membrane protein LMP-1. J Virol 67: 2637- 2645.
41. Raab-Traub N, Flynn K. 1986. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47: 883- 889.
42. Rickinson AB, Kieff E. 2007. In: Epstein-Barr Virus and Its Replication, Knipe D, Howlry P, editors. Fields Virology 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins, pp 2603- 2654.
43. Rowe M, Peng-Pilon M, Huen DS, Hardy R, Croom-Carter D, Lundgren E, Rickinson AB. 1994. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: A B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 68: 5602- 5612.
44. Saechan V, Mori A, Mitarnun W, Settheetham-Ishida W, Ishida T. 2006. Analysis of LMP1 variants of EBV in Southern Thailand: Evidence for strain-associated T-cell tropism and pathogenicity. J Clin Virol 36: 119- 125.
45. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A, Kieff E. 1990. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64: 4084- 4092.
46. Sandvej K, Peh SC, Andresen BS, Pallesen G. 1994. Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 84: 4053- 4060.
47. Sandvej K, Munch M, Hamilton-Dutoit S. 1996. Mutations in the Epstein-Barr virus latent membrane protein-1 (BNLF-1) gene in spontaneous lymphoblastoid cell lines: Effect on in vitro transformation associated parameters and tumorigenicity in SCID and nude mice. Clin Mol Pathol 49: M290- M297.
48. Sung NS, Edwards RH, Seillier-Moiseiwitsch F, Perkins AG, Zeng Y, Raab-Traub N. 1998. Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China. Int J Cancer 76: 207- 215.
49. Tacyildiz N, Cavdar AO, Ertem U, Oksal A, Kutluay L, Uluoglu O, Lin JC. 1998. Unusually high frequency of a 69-bp deletion within the carboxy terminus of the LMP-1 oncogene of Epstein-Barr virus detected in Burkitt's lymphoma of Turkish children. Leukemia 12: 1796- 1805.
50. Tan EL, Peh SC, Sam CK. 2003. Analyses of Epstein-Barr virus latent membrane protein-1 in Malaysian nasopharyngeal carcinoma: High prevalence of 30-bp deletion, Xho1 polymorphism and evidence of dual infections. J Med Virol 69: 251- 257.
51. Terzic TT, Boricic MI, Pendjer IP, Ruzic Zecevic, Tomanovic DT, Brasanac NR, Boricic DC IV. 2010. Prognostic significance of clinical parameters and Epstein-Barr virus infection in non-endemic undifferentiated carcinoma of nasopharyngeal type: A Serbian report. Med Oncol DOI: 10.1007/s12032-010-9551-y Online First™ (Epub ahead of print).
52. Trimeche M, Korbi S, Ziadi S, Amara K, Boniver J, de Leval L. 2005. Molecular characterization of Epstein-Barr virus associated with classical Hodgkin's lymphoma in Tunisia: Prevalence of the LMP1 oncogene deletions and A and B viruses strains. Ann Biol Clin (Paris) 63: 193- 199.
53. Vallat-Decouvelaere AV, Bretel MA, Vassias I, Laplanche JL, Polivka M, Wassef M, Brunet M, Thiebaut JB, Gosselin B, Moriet F, Mikol J. 2002. High frequency of a 30-bp deletion of Epstein-Barr virus latent membrane protein 1 gene in primary HIV non-Hodgkin's brain lymphomas. Neuropathol Appl Neurobiol 28: 471- 479.
54. Wang D, Liebowitz D, Kieff E. 1985. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43: 831- 840.
55. Weiss LM, Movahed LA, Warnke RA, Sklar J. 1989. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 320: 502- 506.
56. Zhang XS, Song KH, Mai HQ, Jia WH, Feng BJ, Xia JC, Zhang RH, Huang LX, Yu XJ, Feng QS, Huang P, Chen JJ, Zeng YX. 2002. The 30-bp deletion variant: A polymorphism of latent membrane protein 1 prevalent in endemic and non-endemic areas of nasopharyngeal carcinomas in China. Cancer Lett 176: 65- 73.